Loading clinical trials...
Loading clinical trials...
Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
Conditions
Interventions
Siltuximab
The M.D. Anderson Symptom Inventory (MDASI)
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
December 14, 2017
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
November 4, 2025
NCT06679101
NCT05969860
NCT06057402
NCT06383143
NCT06870760
NCT07523555
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions